workers, janitors, food service workers, and housekeepers) who met eligibility criteria were recruited for a health survey from general population Internet panels operated by Survey Sampling International (SSI) that provide panel members with online survey opportunities in exchange for nominal incentives. † HCP were recruited through e-mails and messages on the list or panel websites and were eligible for the survey if they reported working in at least one of eight health care settings or reported any patient contact.
Survey elements included demographic characteristics, occupation, work setting, self-reported influenza vaccination, and employer vaccination policies (i.e., vaccination requirements, vaccination availability at the workplace, and promotion of vaccination including recognition, rewards, reminders, compensation, and free or subsidized vaccination). Survey responses were used to categorize HCP into seven occupation and four work setting groups for this analysis. The occupation types were 1) physicians, 2) nurse practitioners/physician assistants, 3) nurses, 4) pharmacists, 5) assistants/aides, 6) other clinical HCP, § and 7) nonclinical HCP. The work settings were: 1) hospitals, 2) ambulatory care/physician offices, 3) LTC settings, and 4) other clinical settings. ¶ Respondents could specify working in more than one work setting. Responses were weighted to the distribution of the U.S. population of HCP by occupation, age, sex, race/ethnicity, work setting, and census region.** Vaccination coverage estimates from opt-in Internet panel surveys conducted during the 2010-11 through 2014-15 influenza seasons were compared with assess trends over time. Similar methodology was used for all five influenza seasons, although Internet panels used to recruit both clinical and nonclinical HCP in 2010-11 differed from those used in subsequent years (6) . Because the study sample was based on HCP from opt-in Internet panels rather than probability samples, no statistical tests were performed. † † A change was 
Occupation type
Nonclinical personnel § § * Persons who worked in a place where clinical care or related services were provided to patients, or whose work involved face-to-face contact with patients or who were ever in the same room as patients. † Ambulatory care (physician's office, medical clinic, and other ambulatory care setting). § Dentist office or dental clinic, pharmacy, laboratory, public health setting, health care education setting, emergency medical services setting, or other setting where clinical care or related services was provided to patients. ¶ Individual data on pharmacists were not collected before the 2012-13 season. ** Included dentists in 2010-11 season.
† † Allied health professionals, technicians, and technologists. § § Administrative support staff members or manager and nonclinical support staff members (including food service workers, laundry workers, janitors, and members of the housekeeping and maintenance staffs). noted as an increase or decrease when there was at least a 5 percentage point difference between estimates; estimates with smaller differences were considered similar. Among the 2,012 HCP who started the survey from either source (Medscape or SSI) and had eligible responses to the screening questions, 1,957 (97.3%) completed the survey. § § Forty-three respondents with completed surveys who reported working in "other health care settings" were excluded because examination of other survey responses indicated that they were either unlikely to have contact with patients or that their work setting was not one of the health care settings of interest for this analysis, leaving a final analytic sample of 1,914 HCP. Overall, 77.3% of HCP reported receiving an influenza vaccination during the 2014-15 season, an increase of 13.8 percentage points compared with the 2010-11 season estimate, but similar to the 75.2% coverage estimate reported in 2013-14 (Figure, Table 1 ).
With the exception of LTC settings, coverage had increased in all work settings since the 2010-11 season ( Figure) ; however, for all work settings, coverage in the 2014-15 season was similar to coverage in the 2013-14 season (Figure, HCP working in settings with employer vaccination requirements had the highest influenza vaccination coverage (Table 2) . During the 2014-15 season, vaccination coverage was 96.0% among HCP working in settings where vaccination was required. Overall, 40.1% of surveyed HCP were required to be vaccinated against influenza, an increase from 20.9% in the 2011-12 season. HCP working in hospitals were most likely to be required to be vaccinated (64.8%), with vaccination coverage of 97.2%, and HCP working in LTC settings were least likely to be required to be vaccinated (26.0%), with vaccination coverage of 97.3%. The lowest vaccination coverage in worksites with employer requirements was 85.7% among HCP in other clinical settings. Among HCP without an employer requirement for vaccination, vaccination coverage among HCP who worked in locations where their employer made vaccination available on-site at no cost for >1 day was 83.9%, compared with coverage of 73.6% among HCP who
Summary
What is already known on this topic?
The Advisory Committee on Immunization Practices recommends annual influenza vaccination for all health care personnel (HCP) to reduce influenza-related morbidity and mortality in health care settings. Estimated overall HCP vaccination coverage was 75.2% for the 2013-14 season.
What is added by this report?
Influenza vaccination coverage among HCP during the 2014-15 influenza season, assessed using an opt-in Internet panel survey, was 77.3%, similar to coverage during the 2013-14 season. Vaccination coverage was highest among physicians, pharmacists, nurse practitioners and physician assistants, nurses, and HCP working in hospital settings. Coverage was lowest among assistants/aides and HCP working in long-term care settings. Offering vaccination at the workplace at no cost was associated with higher vaccination coverage.
What are the implications for public health practice? Worksites using vaccination requirements or, in the absence of requirements, offering at no cost influenza vaccination on-site over multiple days can achieve high HCP vaccination coverage. Including such measures in comprehensive worksite intervention strategies will be important to ensure HCP and patients are protected against influenza.
worked in locations where their employer made vaccination available at no cost for 1 day only and 59.5% among HCP who worked in locations where their employer did not provide influenza vaccination on-site at no cost but actively promoted vaccination through other mechanisms. ¶ ¶ Vaccination coverage was lowest (44.0%) among HCP working in locations where employers neither required vaccination, provided vaccination on-site, nor promoted vaccination. HCP working in LTC settings were most likely to report that their employer neither required, provided, nor promoted vaccination (30.0%), compared with HCP working in other health care settings. In contrast, only 2.6% of HCP working in hospitals reported that their employer neither required, provided, nor promoted vaccination (Table 2) .
Discussion
The overall HCP influenza vaccination coverage estimate for the 2014-15 season was 77.3%, similar to the previous influenza season but higher than the 2010-11 through 2012-13 seasons (6) . As in previous influenza seasons, higher vaccination coverage among HCP was associated with employer § § A survey response rate requires specification of the denominator at each stage of sampling. During recruitment of an online opt-in survey sample, such as the Internet panels described in this report, these numbers are not available; therefore, a response rate cannot be calculated. Instead, the survey cooperation rate is provided. ¶ ¶ Influenza vaccination was promoted among employees through public identification of vaccinated persons, financial incentives, or rewards to individuals or groups of employees, competition between units or care areas, free or subsidized cost of vaccination, personal reminders to be vaccinated, or publicizing of the number or percentage of employees receiving vaccination.
vaccination requirements or access to vaccination at the workplace at no cost for more than 1 day (6). Access to influenza vaccination at the worksite has been associated with higher vaccination coverage among HCP in previous studies (6, 8) . These findings support recommendations for a comprehensive strategy that includes easy access to vaccination at no cost on multiple days, along with promotion of vaccination, to increase HCP influenza vaccination coverage (1, 7) . Coverage among HCP working in LTC settings was the lowest among the work settings examined, a finding that was consistent with the previous three seasons (6) . Influenza vaccination among HCP in LTC settings is important because * Persons who worked in a place where clinical care or related services were provided to patients, or whose work involved face-to-face contact with patients or who were ever in the same room as patients. † Weights were calculated based on each occupation type, by age, sex, race/ethnicity, work setting, and U.S. Census region to represent the U.S. population of HCP. Work setting and overall occupation are presented as weighted estimates of the total sample. Where the groups are stratified by work setting, the estimates are presented as weighted estimates of the occupation group subsample of each work setting subgroup. § Includes all respondents who indicated that their employer required them to be vaccinated for influenza. ¶ Ambulatory care (physician's office, medical clinic, and other ambulatory care setting). ** Dentist office or dental clinic, pharmacy, laboratory, public health setting, health care education setting, emergency medical services setting, or other setting where clinical care or related services was provided to patients. † † Vaccination coverage estimate not reliable because the sample size was <30. § § Employer made influenza vaccination available on-site for >1 day during the influenza season at no cost to employees. Restricted to respondents without an employer requirement for vaccination. ¶ ¶ Employer made influenza vaccination available on-site for 1 day during the influenza season at no cost to employees. Restricted to respondents without an employer requirement for vaccination. *** Influenza vaccination was promoted among employees through public identification of vaccinated persons, financial incentives, or rewards to individuals or groups of employees, competition between units or care areas, free or subsidized cost of vaccination, personal reminders to be vaccinated, or publicizing of the number or percentage of employees receiving vaccination.
influenza vaccine effectiveness is generally lowest in the elderly, making vaccination of close contacts even more critical (3). In addition, multiple studies have demonstrated that vaccination of HCP in LTC settings confers a health benefit to patients, including reduced risk for mortality (2) (3) (4) . HCP working in LTC settings were least likely to report that their employer required vaccination or made vaccination available on-site at no cost for multiple days. Implementing strategies shown to improve HCP workplace vaccination coverage, including vaccination requirements or offering at no cost on-site vaccinations over multiple days, can help protect LTC patients from influenza (7) . HCP working in hospitals had the highest vaccination coverage and were the most likely to report that their employer required vaccination. Higher vaccination coverage and increased use of vaccination requirements and promotion in hospitals compared with other settings might be partly attributable to the Centers for Medicare and Medicaid Services (CMS) requirement in place since January 2013 to report HCP influenza vaccination levels as part of its hospital quality reporting programs (9) . CMS has since added HCP influenza vaccination to quality reporting programs for other HCP work settings, which might affect vaccination coverage in nonhospital settings in future years; however, not all work settings are included in the program.
The findings in this report are subject to at least three limitations, all of which have been described previously (6) . First, the sample was not randomly selected from HCP in the United States. The survey used a nonprobability sample of volunteer HCP members of Medscape and SSI Internet panels and the results based on this nonprobability sample might not be representative of the HCP population in the United States, in particular, those without internet access. Second, influenza vaccination coverage among HCP from the opt-in Internet panel survey (72.0%) differed from the population-based sample in the National Health Interview Survey in the 2009-10 through 2012-13 influenza seasons (66.9% for the 2012-13 season), although trends in coverage were similar across seasons (10) (CDC, unpublished data, 2015). Finally, all results were based on self-report and might be subject to recall bias.
The highest HCP vaccination coverage was reported in worksites with employer requirements for vaccination. In the absence of vaccination requirements, expanding the number of health care locations offering vaccination on-site, over multiple days, and at no cost might help sustain and improve influenza vaccination coverage among HCP. Employers and health care administrators can make use of the Guide to Community Preventive Services, which has found evidence to support onsite vaccination at no or low cost to HCP to increase influenza vaccination coverage among HCP (7) . LTC employers can also use the LTC web-based toolkit*** developed by CDC and the National Vaccine Program Office, which provides access to resources, strategies, and educational materials for increasing influenza vaccination among HCP in LTC settings.
Pregnant women and infants are at increased risk for influenza-related complications and hospitalization. Influenza vaccination can reduce the risk for influenza-related illness among pregnant women and their infants (1) . Since 2004, the Advisory Committee on Immunization Practices (ACIP) and the American College of Obstetricians and Gynecologists (ACOG) have recommended influenza vaccination for all women who are or will be pregnant during the influenza season, regardless of trimester of pregnancy (1, 2) . To assess influenza vaccination coverage among pregnant women during the 2014-15 influenza season, CDC analyzed data from an Internet panel survey conducted during March 31-April 6, 2015. Among 1,702 survey respondents who were pregnant at any time during October 2014-January 2015, 50.3% reported receiving influenza vaccination before or during pregnancy, similar to the reported coverage in the preceding season (3). Overall, 64.9% of respondents reported receiving a provider offer of influenza vaccination, 14.8% received a recommendation but no offer, and 20.3% received no recommendation. Vaccination coverage among these groups of women was 67.9%, 33.5%, and 8.5%, respectively. Reminder systems and standing orders that allow health care personnel other than the attending provider to assess vaccination status and administer vaccination, can help to ensure that influenza vaccination is recommended and offered to a pregnant woman at each provider visit to increase pregnant women's vaccination coverage (4, 5) .
Since the 2010-11 influenza season, CDC has conducted an Internet panel survey annually each April to provide end-ofseason influenza vaccination coverage estimates among pregnant women. For the 2014-15 influenza season, the Internet panel survey was conducted during March 31-April 6, 2015 for CDC by Abt Associates, Inc., to 1) provide end-of-season estimates of influenza vaccination coverage among pregnant women; 2) assess respondent-reported provider recommendation for and offer of influenza vaccination; and 3) obtain updated information on pregnant women's knowledge, attitudes, and behaviors related to influenza vaccination. Women aged 18-49 years who reported being pregnant at any time since August 2014 were eligible to participate in the survey. Participants were recruited from a preexisting, national, opt-in, general population Internet panel operated by Survey Sampling International, which provides panel members with online survey opportunities in exchange for nominal incentives.* Pregnant women panelists were recruited through 1) an email invitation sent to female panel members aged 18-49 years living in the United States, and 2) a message on the panel website inviting panel members to answer a series of screening questions and, if eligible, to take the survey. Among 12,533 women who entered the survey site during March 31-April 6, 2015, 2,171 were determined to be eligible, and 2,053 completed the survey (completion rate † = 94.6%). Data were weighted to reflect the age, race/ethnicity, and geographic distribution of the total U.S. population of pregnant women. A woman was considered to be vaccinated if 1) vaccination was received during July 1, 2014-April 6, 2015 and 2) vaccination was received before or during the most recent pregnancy. The study population was limited to 1,702 women who reported being pregnant any time during the peak influenza vaccination period (October 2014-January 2015). Vaccination coverage estimates for the preceding five seasons were compared to assess trends over time. Similar survey methodology was used in all five seasons (3) .
Survey respondents were asked about their vaccination status (before and/or during pregnancy), whether their provider recommended or offered influenza vaccination, their attitudes regarding influenza and influenza vaccination, and their reasons for receiving or not receiving influenza vaccination. Three composite variables defining attitudes about influenza vaccination efficacy, safety, and concerns about influenza infection were constructed using methods previously described (3) . Because the opt-in Internet panel sample is not probability-based, no statistical tests were performed. § Differences were noted when there was a ≥5 percentage-point difference between any values being compared. * Additional information on the online survey and incentives for participants is available at https://www.surveysampling.com. † An opt-in Internet panel survey is a nonprobability sampling survey. The denominator for a response rate calculation cannot be determined because no sampling frame with a selection probability is involved at the recruitment stage. Instead, the survey completion rate is provided. Completion rate is the percentage of women who completed the survey, among those that were eligible and started the survey. § Additional information on obstacles to inference in non-probability samples is available at http://www.aapor.org/AAPORKentico/default.aspx.
Influenza Vaccination Coverage Among Pregnant
Among the 1,702 women who were pregnant at any time during October 2014-January 2015, 50.3% reported receiving influenza vaccination before pregnancy (15.3%) or during pregnancy (35.0%) since July 1, 2014. The overall vaccination coverage was similar to that in the 2013-14 (52.2%) influenza season ( Table 1) . Non-Hispanic black women reported lower vaccination coverage (38.9%) than did non-Hispanic white women (51.9%). Compared with women in the reference category for each comparison stratum, lower influenza vaccination coverage was reported among women who were aged <35 years, had a college degree or less, were not married, had public insurance or no medical insurance, were not working for wages, were living below the poverty threshold, reported no high-risk conditions associated with increased influenza risk other than pregnancy, reported fewer than six visits to a health care provider since July 2014, and had a negative attitude toward efficacy or safety of influenza vaccination or were not concerned about influenza infection (Table 1) .
Among women with at least one visit to a health care provider since July 2014, women who reported that a provider both recommended and offered influenza vaccination had higher vaccination coverage (67.9%) compared with women who reported receiving a provider recommendation but no offer (33.5%) and women who reported receiving no recommendation for vaccination (8.5%) ( Figure) . Compared with women in the reference category for each comparison stratum, a recommendation for and offer of influenza vaccination was less frequently reported by women who were aged <35 years, See had less than a college degree, were unmarried, did not have medical insurance, were not working for wages, were living below the poverty threshold, did not have high-risk conditions, had fewer than 10 visits to a provider, and had a negative attitude toward influenza vaccination efficacy or safety or were not concerned about influenza infection (Table 2) . Similarly, across all subgroups, influenza vaccination coverage was highest among women whose provider recommended and offered vaccination, followed by women who received only a recommendation but no offer, and lowest among women who received no provider recommendation. Even among women who reported negative attitudes regarding influenza vaccine efficacy or safety, or were not concerned about influenza infection, coverage was higher among those whose provider recommended and offered vaccination than among women with the same beliefs who reported only receiving a provider recommendation or receiving no recommendation ( Table 2) . Among vaccinated women, 86.8% reported that their provider recommended and offered vaccination; among unvaccinated women, the percentage was only 42.3%. The most common reasons women reported for receiving influenza vaccination were "to protect my baby from flu" (33.1%), "to protect myself from flu" (21.4%), and "my doctor, nurse, or other medical professional recommended the flu vaccination" (15.0%). The most common reasons women reported for not receiving vaccination were "I don't think the vaccination is effective in preventing flu" (17.2%), "I have concerns about possible safety risk to my baby if I got vaccinated" (14.5%) and "I am concerned that the vaccination would give me the flu" (13.6%).
Discussion
During the 2014-15 influenza season approximately half of surveyed pregnant women had received influenza vaccination, similar to the percentages found for the 2013-14 (52.2%), 2012-13 (50.5%), and 2011-12 (46.4%) influenza seasons, ¶ Working status: Yes = those employed for wages and self-employed; No = those out of work, homemakers, students, retired, or unable to work. ** As determined by the U.S. Census Bureau (http://www.census.gov/hhes/www/poverty/data/threshld), for the 2014-15 season below poverty = total family income of <$24,008 for a family of four with two minors as of 2014; for the 2013-14 season below poverty = total annual family income of <$23,624 for a family of four with two minors as of 2013. † † Conditions associated with increased risk for serious medical complications from influenza, including chronic asthma, a lung condition other than asthma, a heart condition, diabetes, a kidney condition, a liver condition, obesity, or a weakened immune system caused by a chronic illness or by medicines taken for a chronic illness. § § Vaccination coverage estimate was not reliable because sample size was <30. ¶ ¶ Excluding women who had not visited a health care provider since July 2013 (n = 16) for the 2013-14 influenza season, and who had not visited a health care provider since July 2014 (n = 18) for the 2014-15 influenza season. *** Created based on two questions regarding attitudes toward the efficacy of flu vaccination: 1) "Flu vaccine is somewhat/very effective in preventing flu, " and 2) "Flu vaccine a pregnant women received is somewhat/very effective in protecting her baby from the flu. " A 1-point score was given for each "yes" answer for either of the two questions. "Positive" attitude = summary score of 1 or 2; "Negative" attitude = summary score of 0. † † † Created based on three questions regarding attitudes toward the safety of flu vaccination: 1)"Flu vaccination is somewhat/very/completely safe for most adult women"; 2) "Flu vaccination is somewhat/very/completely safe for pregnant women"; and 3) "Flu vaccination that a pregnant woman receives is somewhat/very/ completely safe for her baby. " 1 point was given for each "yes" answer for any of the 3 questions. "Positive" attitude = summary score of 2 or 3; "Negative" attitude = summary score of 0 or 1. § § § Created based on three questions regarding attitude toward flu infection: 1) "If a pregnant woman gets the flu, it is somewhat/very likely to harm the baby"; 2) "Flu infection during pregnancy somewhat/very likely harms pregnant women"; and 3) "somewhat/very worried about getting sick with the flu this season . " 1 point was given for each "yes" answer for any of the 3 questions. "Concerned" = summary score of 2 or 3; "Not concerned" = summary score of 1 or 0.
but higher than those found for the 2010-11 season (44.0%) (3). A substantially higher percentage of women who reported that their provider both recommended and offered influenza vaccination had received influenza vaccine compared with women who reported receiving only a recommendation but no offer or no recommendation; however, the percentage of women receiving a provider offer and recommendation was similar to last season. The higher coverage reported among pregnant women whose provider recommended and offered influenza vaccination, including women with negative attitudes about influenza vaccine efficacy or safety, or who were not concerned about getting influenza, highlights the importance of a provider recommendation for influenza vaccination coupled with an offer of influenza vaccination onsite to increase vaccination coverage among pregnant women. Implementing and strengthening systems that support provider ability to recommend and offer influenza vaccination to pregnant women, including standing orders and provider reminder systems, as well as expanded access to vaccination services in expanded health care settings, such as pharmacies, can increase opportunities for vaccination and improve coverage (4, 5) .
Similar to previous seasons, vaccination coverage was lower among black women than white women, despite a similar percentage of black and white women reporting receiving a provider recommendation and offer of vaccination, highlighting the need to identify and address possible factors contributing to this disparity, which might include weaker or less effective provider recommendations, differences in sociocultural norms, misperception of vaccine effectiveness and safety, vaccination resistance and hesitancy, and poorer quality of provider-patient relationships (6, 7) .
Unlike the previous influenza seasons, during the 2014-15 season the most commonly reported reason for not being vaccinated concerned lack of confidence in influenza vaccine efficacy, which might have reflected knowledge about the mismatch of the influenza vaccine with the circulating strain in the 2014-15 season (3, 8) . In addition to addressing this concern, clinic-based client education for pregnant women should emphasize that influenza vaccination during pregnancy is safe and can protect not only pregnant women themselves but also their infants during the first 6 months of life when they are too young to receive vaccination (1, 2, 4) . This education needs to be supported by provider recommendation for and offer of influenza vaccination during the visit (4). Education messages can be delivered through multiple channels, including prenatal care consultation, social media, and text messaging (e.g., applications such as https://text4baby.org).
The findings in this report are subject to at least four limitations. First, vaccination was self-reported and not validated by medical records; therefore, coverage might be over-or underestimated. Second, the study sample did not include women without Internet access. Therefore, results are not generalizable to all pregnant women in the United States. Third, the Internet panel survey is an opt-in survey and estimates might be biased What is added by this report?
During the 2014-15 influenza season, 50.3% of pregnant women were vaccinated before or during pregnancy, similar to the 2013-14 season. Women who received a provider offer of vaccination had substantially higher vaccination coverage than those who did not receive an offer of vaccination. Barriers to vaccination included negative attitudes about safety and efficacy of influenza vaccination and unfounded concern that vaccination would cause influenza.
What are the implications for public health practice?
To protect mothers and their babies from complications of influenza, efforts are needed to improve influenza vaccination coverage among pregnant women. Interventions should include implementing clinic-based education to ensure access to information about influenza vaccine safety and efficacy and the risk for influenza for pregnant women and their infants, and systems to ensure that providers recommend and offer influenza vaccination to all pregnant women.
if a woman's decision to participate in this particular survey were related to receipt of vaccination. Fourth, the composite variables computed for attitudes toward influenza vaccination and infection were not validated. Despite these limitations, the opt-in Internet panel survey can provide timely estimates of influenza vaccination coverage and in-depth information about knowledge, attitudes, behaviors, and barriers related to influenza vaccination among pregnant women. Trends in vaccination coverage reported from the Internet panel surveys have been consistent with those reported from less timely probability sampling surveys (9) .
The data from the current analysis demonstrate that to improve vaccination coverage, pregnant women receiving a provider recommendation for and offer of influenza vaccination is important, as is clinic-based education about the safety and efficacy of vaccination toward pregnant women. Missed opportunities for vaccination can be reduced by implementing standing orders that enable appropriately trained health personnel to administer vaccinations without the need for examination or a direct order from the provider at the time of the interaction, and provider reminders to ensure influenza vaccination is recommended and offered at each visit before and during pregnancy. Providing referrals in situations where a provider is unable to offer vaccination could help pregnant women receive influenza vaccination. Many unvaccinated women in this survey reported receiving a provider recommendation or offer to be vaccinated yet reported being unvaccinated, emphasizing the need for clinic-based education to address concerns about vaccination during pregnancy. Resources are available from CDC (http://www.cdc.gov/flu/protect/vaccine/pregnant.htm) to help providers communicate the risk for influenza and benefits of vaccination for pregnant women. gov/hhes/www/poverty/data/threshld/). † † Conditions associated with increased risk for serious medical complication from influenza, including chronic asthma, a lung condition other than asthma, a heart condition, diabetes, a kidney condition, a liver condition, obesity, or a weakened immune system caused by a chronic illness or by medicines taken for a chronic illness. § § Created based on two questions regarding attitudes toward the efficacy of flu vaccination: 1) "Flu vaccine is somewhat/very effective in preventing flu, " and 2) "Flu vaccine a pregnant women received is somewhat/very effective in protecting her baby from the flu. " A 1-point score was given for each "yes" answer for either of the two questions. "Positive" attitude = summary score of 1 or 2; "Negative" attitude = summary score of 0. ¶ ¶ Created based on three questions regarding attitudes toward the safety of flu vaccination: 1)"Flu vaccination is somewhat/very/completely safe for most adult women"; 2) "Flu vaccination is somewhat/very/completely safe for pregnant women"; and 3) "Flu vaccination that a pregnant woman receives is somewhat/very/ completely safe for her baby. " A 1-point score was given for each "yes" answer for any of the 3 questions. "Positive" attitude = summary score of 2 or 3; "Negative" attitude = summary score of 0 or 1. *** Created based on three questions regarding attitude toward flu infection: 1) "If a pregnant woman gets the flu, it is somewhat/very likely to harm the baby"; 2) "Flu infection during pregnancy somewhat/very likely harms pregnant women"; and 3) "somewhat/very worried about getting sick with the flu this season. " A 1-point score was given for each "yes" answer for any of the 3 questions. "Concerned" = summary score of 2 or 3; "Not concerned" = summary score of 1 or 0. The 2014-2015 Ebola virus disease (Ebola) epidemic is the largest in history and represents the first time Ebola has been diagnosed in the United States (1,2). On July 9, 2014, CDC activated its Emergency Operations Center and established an Ebola clinical consultation service to assist U.S. state and local public health officials and health care providers with the evaluation of suspected cases. CDC reviewed all 89 inquiries received by the consultation service during July 9, 2014-January 4, 2015, about children (persons aged ≤18 years). Most (56 [63%]) children had no identifiable epidemiologic risk factors for Ebola; among the 33 (37%) who did have an epidemiologic risk factor, in every case this was travel from an Ebola-affected country. Thirty-two of these children met criteria for a person under investigation (PUI) because of clinical signs or symptoms (3, 4) . Fifteen PUIs had blood samples tested for Ebola virus RNA by reverse transcription-polymerase chain reaction; all tested negative. Febrile children who have recently traveled from an Ebola-affected country can be expected to have other common diagnoses, such as malaria and influenza, and in the absence of epidemiologic risk factors for Ebola, the likelihood of Ebola is extremely low. Delaying evaluation and treatment for these other more common illnesses might lead to poorer clinical outcomes. Additionally, many health care providers expressed concerns about whether and how parents should be allowed in the isolation room. While maintaining an appropriate level of vigilance for Ebola, public health officials and health care providers should ensure that pediatric PUIs receive timely triage, diagnosis, and treatment of other more common illnesses, and care reflecting best practices in supporting children's psychosocial needs (5).
The Community Preventive
CDC's Emergency Operations Center was activated to respond to the Ebola outbreak in West Africa. A clinical consultation service was established to assist state and local health departments and health care providers evaluate persons possibly at risk for Ebola. Children with any signs or symptoms consistent with Ebola (fever, nausea, vomiting, headache, diarrhea, abdominal pain, muscle pain, fatigue, or unexplained bleeding) and an epidemiologic risk factor (i.e., exposure to a person with Ebola or travel from an affected country during the 21 days before symptom onset) were considered PUIs (3, 4) . Ebola assessment can take ≥3 days, because the diagnosis cannot be ruled out until a blood specimen obtained 72 hours after symptom onset is negative for Ebola (6) . Ebola testing might not be necessary if an alternative diagnosis is made or if symptoms resolve. All domestic Ebola diagnoses are confirmed at CDC or at local or state public health laboratories, most of which are part of the CDC Laboratory Response Network (7). All Ebola-related inquiries about children during July 9, 2014-January 4, 2015 were reviewed, including call logs and e-mails, as well as databases that contain the inquiry source, demographic information, epidemiologic risk factors, clinical presentation and course, isolation measures, Ebola virus test results, and discharge diagnoses, if available (3).
During July 9, 2014-January 4, 2015, CDC responded to clinical inquiries regarding 89 children in 27 states and the District of Columbia. CDC received an average of 1-2 Ebolarelated inquiries about children per week (range = zero to eight) before September 30, 2014, when CDC confirmed the first imported Ebola case identified in the United States (Figure) (2) . In the subsequent 4 weeks, calls increased, with CDC receiving an average of 12 pediatric Ebola-related inquiries per week (range = five to 25). However, only 20% (10 of 49) of these inquiries turned out to involve actual PUIs, significantly lower than the 55% (22 of 40 [p<0.01]) of pediatric Ebola-related inquires that involved PUIs during all other weeks combined.
Overall, 57 (64%) children about whom an Ebola-related inquiry was made did not meet PUI criteria. Among these, 56 had no identifiable epidemiologic risk factors for Ebola but nevertheless were perceived by the inquirer to be at risk. The most common misperception about risk involved confusion about which countries were affected by Ebola: 30 (54%) children had traveled from an unaffected country, seven (12%) had contact with a traveler from an unaffected country, and 15 (27%) were perceived erroneously to have been exposed to Ebola inside the United States. Most of these inquiries (49 of 56) were initiated by a health care provider; most (37) occurred during the 4 weeks after the first Ebola case was diagnosed in the United States.
Demographic characteristics were similar for children with and without epidemiologic risk factors (Table 1) . Among 33 children with an epidemiologic risk factor for Ebola, all had traveled to an Ebola-affected country, and none had known contact with an Ebola patient; 32 (97%) also had one or more signs or symptoms consistent with Ebola and thus were (Table 2 ). Discharge diagnosis information was available for 19 (59%) PUIs; diagnoses included malaria (five), influenza (five), other viral illness (three), and other nonviral illness (six). At health care facilities, at least 15 PUIs were placed in some form of isolation during evaluation, and at least 10 were transferred to another hospital for Ebola assessment. Intensive care was required for at least three children while they were being evaluated; diagnoses included malaria, dehydration, and nonspecific viral illness. Written records suggest that appropriate clinical care was delayed for at least five children, either because of difficulty finding a hospital to evaluate a pediatric PUI or hospital reluctance to perform testing in the laboratory for illnesses such as malaria and influenza, because of concern about potential laboratory contamination or exposure of staff members to Ebola. One PUI who received routine vaccinations within 21 days of travel from an Ebola-affected country developed a fever 2 days later and required a full clinical evaluation to determine whether the fever was related to the vaccines, Ebola, or another travel-related illness. During pediatric Ebola assessments, many health care providers expressed concerns about whether children's parents should be permitted in the isolation room and how to manage their presence. Health care facility challenges included a lack of established policies about parental presence with children in isolation, limited supplies of personal protective equipment (PPE), lack of available staff to supervise parental donning and doffing of PPE, and insufficient time to teach parents proper PPE use. In several instances, cell phone or laptop-based video connections were used to connect isolated school-aged children with their relatives in another room.
Discussion
Pediatric clinical care presents unique challenges during an Ebola assessment (5, 8) , and routine pediatric care for common pediatric illnesses (e.g., bacterial and viral infections, or malaria, a disease that is endemic in West Africa) was sometimes delayed because of concerns about Ebola. No child evaluated for Ebola had any known contact with an Ebola patient or their body fluids, or with a deceased patient, and to date, no pediatric Ebola case has been identified or managed in the United States. In light of this low risk, children can be expected to have other more common causes of febrile illness, and delaying evaluation and treatment of these other diagnoses might lead to poorer clinical outcomes. Malaria and influenza should be considered in the differential diagnosis of fever in travelers, and early testing and treatment can prevent severe illness (5) . Furthermore, recent travelers and immigrant children, in particular, have specific health care needs, such as routine and catch-up vaccinations. Vaccine providers should be aware of the potential for vaccine-associated fever and can consult their local or state health department for assistance in weighing the benefits and risks of administering routine vaccinations to children who are under active monitoring for Ebola because they have traveled to the United States from an affected area during the preceding 21 days.
Children, especially those who are young or who have developmental delays, are dependent upon caregivers to provide physical, emotional, and social support. The presence of a parent or caregiver in the examination room during the clinical assessment for Ebola might be important for many pediatric patients, especially very young children. Risks and benefits of parental presence should be considered on a case-by-case basis. Parents or caregivers who provide bedside support to a child in isolation for an Ebola assessment should use PPE consistently, correctly, and in accordance with CDC guidance, state or local health department recommendations, and facility policies (9) . Health care facilities that might perform pediatric Ebola assessments can anticipate and plan for issues specifically related to caring for a child, including establishing policies and plans for parental presence, PPE use, and communication. Transfers of pediatric patients between facilities for Ebola-related care involve challenges related to communication between clinical teams and health departments, infection control during transport, operations coordination, and other concerns (9, 10) .
Although the weekly number of pediatric PUIs varied little, the number of clinical inquiries related to children increased sharply during the month after the first domestic Ebola case (Figure) . Most of these children did not meet PUI criteria, but all inquiries required rapid, accurate, and complete evaluation. By anticipating and planning for surges, public health officials can scale responses to meet changing community needs. Proactive steps, including clear and consistent risk communication, timely clinician education, and broad community outreach might reduce public misperception about Ebola risk and lessen strain on clinical and public health resources. The findings in this report are subject to at least two limitations. First, clinical data and information regarding isolation and PPE were collected as part of a public health emergency response, and information on certain variables (e.g., symptoms, suspected exposure, and alternative diagnoses) might be incomplete. Second, although this report describes all domestic Ebola-related pediatric clinical inquiries to CDC, it might not include all inquiries to health departments.
During this epidemic, CDC, state and local public health departments, and health care providers developed strategies to monitor travelers and others who might be at risk for Ebola. The goals are to quickly isolate and evaluate PUIs, including children, to ensure that patients receive timely care while minimizing transmission risk. CDC provides up-to-date information about Ebola online at http://www.cdc.gov/vhf/ebola. While maintaining a high level of vigilance for Ebola among ill pediatric patients who have recently travelled from affected countries, U.S. public health officials and health care providers should provide child-focused care that includes timely diagnosis and appropriate treatment of common pediatric illnesses, as well as Ebola, and reflects overall best practices in supporting children's psychosocial needs. 
Summary
The current epidemic of Ebola virus disease (Ebola) is the largest in history and represents the first time Ebola has been diagnosed in the United States. CDC's Emergency Operations Center offers consultation to state and local health departments and health care providers assessing adults and children for Ebola.
What is added by this report? During July 9, 2014-January 4, 2015, CDC responded to clinical inquiries regarding 89 children in the United States. Only 33 had an epidemiologic risk factor; 15 were tested for Ebola. All were negative. Medical evaluation and treatment for other conditions were sometimes delayed while the child underwent Ebola assessment. Additionally, health care providers and hospitals expressed concerns about allowing parents in the isolation room.
What are the implications for public health practice?
Public health and health care providers in the United States, while maintaining a high level of vigilance for Ebola among ill pediatric patients, should be prepared to provide child-focused care that includes timely diagnosis and treatment of common pediatric illnesses, as well as Ebola, and reflects overall best practices in supporting children's psychosocial needs. Parents or caregivers who provide bedside support to a child in isolation for Ebola evaluation should use personal protective equipment in accordance with CDC guidance, health department recommendations, and facility policies. 
United States
The U.S. influenza surveillance system § is a collaboration between CDC and federal, state, local, and territorial partners, and uses eight data sources to collect influenza information, ¶ six of which operate year-round.
During May 24-September 5, 2015, World Health Organization (WHO) and National Respiratory and Enteric Virus Surveillance System (NREVSS) collaborating laboratories in the United States tested 80,345 specimens for influenza; 1,698 (2.1%) were positive for influenza (Figure) . Of the 1,698 specimens positive for influenza during the summer months of 2015, a total of 913 (54%) were influenza A viruses, and 785 (46%) were influenza B viruses. Influenza B viruses were reported slightly more frequently than influenza A viruses from late May until mid-June, and influenza A viruses were more commonly reported from late June through early September. Of the 913 influenza A viruses, 551 (60%) were subtyped: 28 (5%) were pH1N1 viruses and 523 (95%) were influenza A (H3N2) viruses. Influenza viruses were reported from the District of Columbia, Puerto Rico, and 47 states in all 10 U.S. Department of Health and Human Services regions.** During May 24-September 5, data from the U.S. Outpatient Influenza-Like Illness Surveillance Network (ILINet) indicated that the weekly percentage of outpatient visits to health care providers for influenza-like illness (ILI) † † remained below the national baseline § § of 2.0%, ranging from 0.8% to 1.3%. The percentage of deaths attributed to pneumonia and influenza (P&I), as reported by the 122 Cities Mortality Reporting System, did not exceed the epidemic threshold ¶ ¶ for 2 consecutive weeks and ranged from 5.0% to 6.4%. A total of four influenza-associated pediatric deaths were reported during May 24-September 5; all were associated with influenza B viruses and occurred during weeks 7, 8, 17 
Novel Influenza A Virus Infection
During May 24-September 5, three cases of human infection with novel influenza A viruses were reported. One infection with an H3N2v virus was reported by Minnesota in July, one infection with an H1N1v virus was reported by Iowa in August, and one infection with an H3N2v virus was reported by Michigan in August. All three patients were hospitalized as a result of their illness, but recovered fully. Direct contact with swine in the week preceding illness onset was reported in all three instances. No ongoing community transmission of either virus was detected.
Worldwide
CDC serves as a WHO Collaborating Center for Surveillance, Epidemiology, and Control of Influenza, one of six WHO Collaborating Centers for Influenza in the WHO Global Influenza Surveillance and Response System (GISRS) (1) . CDC, along with other international public health partners, provide surveillance and virus characterization data to WHO (2) . The timing of influenza activity around the world varies depending on the climate of the region.*** Geographic groups of countries, areas, or territories with similar influenza transmission patterns are grouped by influenza transmission zones (2). *** In temperate climates, the onset and peak of influenza activity might vary substantially from one influenza season to the next, but generally begins to increase in the late fall. In the Northern Hemisphere's temperate regions, annual epidemics of influenza typically occur during October-February, but the peak of influenza activity can occur as late as April or May. In temperate regions of the Southern Hemisphere, influenza activity typically peaks during May through August. Although temperate regions of the world experience a seasonal peak in influenza activity, influenza viruses can be isolated yearround. The timing of seasonal peaks in influenza activity in tropical and subtropical countries varies by region, and multiple peaks of activity during the same year have been seen in some areas.
During May 24-September 5, typical seasonal patterns of influenza activity occurred in temperate climate Southern Hemisphere countries. In Australia, influenza activity began to increase in early June, while influenza activity in New Zealand began to increase in mid-July. Activity in both countries remained elevated as of early September. In Australia and New Zealand, influenza B viruses predominated overall, but the proportion of influenza A (H3N2) viruses increased during July and August. Small numbers of pH1N1 viruses were reported from both countries. In South Africa, influenza activity began to increase in late May, peaked in late June, and decreased in late July. Influenza A (H3N2) and pH1N1 viruses predominated in that country, but influenza B viruses also were reported. In temperate countries of South America, influenza activity began to increase in June, remained elevated through July, and decreased in August. Influenza A viruses were reported more frequently than influenza B viruses, and both pH1N1 and influenza A (H3N2) viruses were detected in Chile and Paraguay. Influenza A (H3N2) viruses predominated in Argentina. In temperate climate countries of Europe and North America, influenza activity was low, and small numbers of pH1N1, influenza A (H3N2), and influenza B viruses were identified.
In countries with tropical influenza seasonality, overall influenza activity remained low, and the predominant virus varied by country. In the Caribbean and Central America, influenza A viruses were more commonly reported, with influenza A (H3N2) viruses predominating in Mexico and El Salvador, while pH1N1 viruses were more frequently reported in Cuba. In tropical South America, influenza A viruses predominated. Influenza A (H3N2) and pH1N1 viruses co-circulated in Colombia and Peru, while influenza A (H3N2) viruses predominated in Brazil and Ecuador; however, influenza B viruses were more frequently reported in Bolivia. In South Asia and Southeast Asia, a decrease in influenza activity was observed during August and September, and influenza A (H3N2) viruses predominated in Cambodia, China, Laos, Philippines, Singapore, Thailand, and Vietnam, with smaller numbers of pH1N1 and influenza B viruses reported. In Indonesia, influenza B viruses were more frequently reported, but influenza A (H3N2) and pH1N1 viruses also were identified. During May 24-September 5, four laboratory-confirmed human cases of avian influenza A (H5N1) virus infection were reported to WHO from Egypt, and one case of influenza A (H5N6) and five cases of influenza A (H7N9) were identified in China. † † †
Antigenic and Genetic Characterization of Influenza Viruses
The 
Antiviral Resistance Profiles of Influenza Virus Isolates
The WHO Collaborating Center for Surveillance, Epidemiology, and Control of Influenza at CDC tested 169 influenza virus specimens collected during May 24-September 5 from the U.S. and worldwide for resistance to the influenza neuraminidase inhibitor antiviral medications; oseltamivir, zanamivir, and peramivir, which are the drugs currently approved for use against seasonal influenza. All 19 (16 international and three U.S.) pH1N1 viruses, 84 (five international and 79 U.S.) influenza A (H3N2) viruses, and 66 (11 international and 55 U.S) influenza B viruses tested were sensitive to all three antiviral medications. High levels of resistance to the adamantanes (amantadine and rimantadine) persist among pH1N1 and influenza A (H3N2) viruses. Adamantane drugs are not recommended for use against influenza at this time.
Discussion
During May 24-September 5, 2015, pH1N1, influenza A (H3N2), and influenza B viruses co-circulated worldwide. In the United States, low levels of influenza activity were reported, and influenza A viruses were more frequently reported from late June to September. All of the influenza viruses collected from U.S. states and other countries during that time were antigenically and/or genetically characterized as being similar to the influenza vaccine viruses recommended for inclusion in the 2015-16 Northern Hemisphere vaccine. Antigenic and genetic characterization of circulating influenza viruses can give an indication of the influenza vaccine's ability to produce an immune response against circulating influenza viruses, but vaccine effectiveness studies are needed to determine how much protection has been provided by vaccination to the community. Last season, low vaccine effectiveness observed against the predominant influenza A (H3N2) viruses was consistent with laboratory data indicating that most influenza A (H3N2) viruses that circulated were antigenically and genetically different (drifted) from the influenza A (H3N2) vaccine component of the 2014-15 Northern Hemisphere influenza vaccines (4). It is not possible to predict which influenza virus will predominate or how severe influenza-related disease activity will be during the 2015-16 season, nor is it possible to say with certainty how effective influenza vaccine will be; however, laboratory analysis of influenza viruses to date suggests that the majority of viruses circulating worldwide in the past few months are similar to 2015-16 vaccine viruses.
Annual influenza vaccination is the best method for preventing influenza and its potentially severe complications (3). While vaccine effectiveness can vary, vaccination has been shown to reduce influenza illnesses, doctors' visits, influenzarelated hospitalizations, and deaths (5, 6) . Even during seasons when vaccine effectiveness is reduced, substantial public health impact can still be measured (6) (7) (8) . In the United States, annual influenza vaccination is recommended for all persons aged ≥6 months who do not have contraindications. Annual influenza vaccination is recommended regardless of whether the vaccine composition has changed because immunity from vaccination might wane after one season. For the 2015-16 influenza season, interim supply projections by manufacturers for the U.S. market range from 171 million and 179 million doses of vaccine. This would to be the largest supply of influenza vaccine distributed in the United States during one season with the exception of the 2009 pandemic.
Multiple influenza vaccines are approved for use and are being distributed during the 2015-16 season, including a quadrivalent live attenuated influenza vaccine (LAIV4), trivalent and quadrivalent inactivated influenza vaccines (IIV3 and IIV4, respectively), a trivalent cell culture-based inactivated influenza vaccine (ccIIV3), a high-dose trivalent inactivated influenza vaccine (hd IIV3), and a recombinant trivalent influenza vaccine (RIV3). One IIV4 formulation also is approved for intradermal administration. Although both LAIV and inactivated influenza vaccine (IIV) have been demonstrated to be effective in children and adults, LAIV is approved for use in persons aged 2 through 49 years with no contraindications or precautions § § § (3). For the 2015-16 season, the Advisory Committee on Immunization Practices recommended that healthy children aged 2 through 8 years who have no contraindications or precautions receive either LAIV or IIV, with no preference expressed for either vaccine when one is otherwise appropriate and available (3) . This removes the 2014-15 preferential recommendation of LAIV for healthy children aged 2 through 8 years (3). For the 2015-16 season, ACIP recommends that children aged 6 months through 8 years who have previously received ≥2 total doses of trivalent or quadrivalent influenza vaccine at any time before July 1, 2015, require only 1 dose for 2015-16 (3). The 2 previous doses do not need to have been given during the same or consecutive seasons (3). Children in this age group who are being vaccinated for the first time or who have not previously received a total of ≥2 doses require 2 doses of influenza vaccine, administered ≥4 weeks apart (9) .
Although vaccination is the best method for preventing and reducing the impact of influenza, antiviral medications are a valuable adjunct. Treatment with influenza antiviral medications is recommended as early as possible for patients with confirmed or suspected influenza (either seasonal influenza or novel influenza virus infection) who have severe, complicated, or progressive illness; who require hospitalization; or who are at high risk for influenza-related complications ¶ ¶ ¶ (10). Antiviral treatment should not be withheld from high-risk or severely ill patients with suspected influenza infection (10). Treatment is most effective when given early in the illness; providers should not delay treatment until test results become available and should not rely on insensitive assays such as rapid antigen detection influenza diagnostic tests to determine treatment decisions (10) .
Influenza surveillance reports for the United States are posted online weekly and are available at http://www.cdc.gov/flu/ weekly. Additional information regarding influenza viruses, influenza surveillance, influenza vaccines, influenza antiviral medications, and novel influenza A virus infections in humans is available at http://www.cdc.gov/flu.
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Summary
What is already known on this topic? CDC collects, compiles, and analyzes data on influenza activity year-round in the United States. The influenza season generally begins in the fall and continues through the winter and spring months; however, the timing and severity of disease and the predominant viral strains can vary by geographic location and season.
Worldwide, influenza activity during May 24-September 5, 2015, was elevated in the temperate Southern Hemisphere and tropical regions, compared with their levels outside the usual influenza season. In the United States, low levels of seasonal influenza activity were detected.
In the United States, an influenza vaccine is recommended for all persons aged ≥6 months and can reduce the likelihood of becoming ill with influenza and transmitting the virus to others. Annual influenza vaccination is recommended for optimal protection regardless of whether the vaccine composition has changed since the previous season because immunity wanes over time. Although vaccination is the best way to prevent influenza, treatment with influenza antiviral medications can reduce severe outcomes of influenza, especially when initiated as early as possible, in patients with confirmed or suspected influenza who have severe, complicated, or progressive illness; who require hospitalization; or who are at high risk for influenza-related complications. § § § LAIV should not be used in the following populations: 1) persons aged <2 years or >49 years; 2) those with contraindications listed in the package insert (children aged 2 through 17 years who are receiving aspirin or aspirincontaining products and persons who have experienced severe allergic reactions to the vaccine or any of its components, or to a previous dose of any influenza vaccine); 3) pregnant women; 4) immunosuppressed persons; 5) persons with a history of egg allergy; 6) children aged 2 through 4 years who have asthma or who have had a wheezing episode noted in the medical record within the past 12 months, or for whom parents report that a health care provider stated that the child had wheezing or asthma within the last 12 months; 7) persons who have taken influenza antiviral medications within the previous 48 hours; and 8) persons who care for severely immunosuppressed persons who require a protective environment (such persons should not receive LAIV, or should avoid contact with immunosuppressed persons for 7 days after receipt, given the theoretical risk for transmission of the live attenuated vaccine virus). ¶ ¶ ¶ Persons at high risk include 1) children aged <5 years (especially those aged <2 years); 2) adults aged ≥65 years; 3) persons with chronic pulmonary (including asthma), cardiovascular (except hypertension alone), renal, hepatic, hematologic (including sickle cell disease), metabolic disorders (including diabetes mellitus), or neurologic and neurodevelopment conditions (including disorders of the brain, spinal cord, peripheral nerve, and muscle, such as cerebral palsy, epilepsy [seizure disorders], stroke, intellectual disability [mental retardation], moderate to severe developmental delay, muscular dystrophy, or spinal cord injury); 4) persons with immunosuppression, including that caused by medications or by human immunodeficiency virus infection; 5) women who are pregnant or postpartum (within 2 weeks after delivery); 6) persons aged ≤18 years who are receiving long-term aspirin therapy; 7) American Indians/Alaska Natives; 8) persons who are morbidly obese (i.e., with a body mass index ≥40); and 9) residents of nursing homes and other chronic care facilities.
National Fall Prevention Awareness DaySeptember 23, 2015
Annually in the United States, 2.5 million persons aged ≥65 years are treated in emergency departments for injuries from falls, resulting in $34 billion in direct medical costs (1) . Given these costs, the aging U.S. population, and the increasing fall death rates (2), falls have become a major risk to the health of older persons in the United States.
In conjunction with the 2015 White House Conference on Aging, CDC launched the implementation of the STEADI (Stopping Elderly Accidents, Deaths, and Injuries) initiative for healthcare providers. STEADI uses established clinical guidelines and scientifically tested interventions to help providers address their patients' risk for falls, identify modifiable risk factors, and provide effective interventions (3). Free online training with continuing education is available and electronic health record vendors (Epic and GE Centricity) are developing STEADI modules to help incorporate fall prevention into clinical practice. For every 5,000 providers adopting STEADI over a 5-year period, one million additional falls could be avoided, saving an additional $3.5 billion in direct medical costs (4) . National Fall Prevention Awareness Day is September 23. As part of the campaign, health care providers are encouraged to do the following:
• Screen patients by asking if they have fallen in the past year, feel unsteady, or worry about falling • Review patients' medications and stop, switch, or reduce the dose of drugs that increase the risk for falls Analyses were conducted using National Immunization Survey influenza vaccination data for children aged 6 months-17 years and Behavioral Risk Factor Surveillance System influenza vaccination data for adults aged ≥18 years. Estimates are provided by age group and race/ethnicity. These estimates are presented in an interactive report (http://www.cdc.gov/ flu/fluvaxview/interactive.htm) and are complemented by an online summary report (http://www.cdc.gov/flu/fluvaxview/ coverage-1415estimates.htm).
Announcements Announcement

National Child Passenger Safety WeekSeptember 13-19, 2015
This year, National Child Passenger Safety Week is September 13-19. In the United States, motor vehicle-related injuries are a leading cause of death among children (1) . In 2013, a total of 638 passenger vehicle occupants aged 0-12 years died as a result of a crash (2) , and more than 127,250 were injured (1) . Of the children that died in 2013, 38% were known to be unrestrained (2) . To keep child passengers as safe as possible, drivers should properly restrain children aged <13 years in age-and size-appropriate restraints in a back seat and follow the American Academy of Pediatrics' child passenger safety recommendations (3) .
As part of National Child Passenger Safety Week, September 19 has been designated as National Seat Check Saturday. On this day, drivers with children who ride in car seats or booster seats are encouraged to visit a child safety seat inspection station to have a certified technician inspect their car seat for proper installation and proper use free of charge. Additional information and an inspection station locator are available from CDC at http://www.cdc.gov/motorvehiclesafety/child_passenger_safety and the National Highway Traffic Safety Administration at http://www.nhtsa.gov/Safety/ CPS. Campaign promotional materials in English and Spanish are available at http://www.trafficsafetymarketing.gov/cps.
Final 2014 Reports of Nationally Notifiable Infectious Diseases
The tables listed in this report on pages 1020-1033 summarize finalized data, as of June 30, 2015, from the National Notifiable Diseases Surveillance System (NNDSS) for 2014. These data will be published in more detail in the Summary of Notifiable Diseases, United States, 2014 (1). Because no cases were reported in the United States during 2014, the following diseases do not appear in these early release tables: anthrax; dengue hemorrhagic fever; eastern equine encephalitis, nonneuroinvasive; poliomyelitis, paralytic; poliovirus infection, nonparalytic; severe acute respiratory syndrome-associated coronavirus disease (SARSCoV); smallpox; vancomycin-resistant Staphylococcus aureus (VRSA); western equine encephalitis virus disease, neuroinvasive and nonneuroinvasive; and yellow fever.
Policies for reporting NNDSS data to CDC can vary by disease or reporting jurisdiction, depending on case status classification (i.e., confirmed, probable, or suspected). The publication criteria used for the 2014 finalized tables are listed in the "Print Criteria" column of the NNDSS event code list, available at http://wwwn.cdc.gov/nndss/document/ nndss_event_code_list_2014.pdf. ---1  3  332  201  Arkansas  2,966  -------9  2  Louisiana  4,650  -------61  64  Oklahoma  3,878  -------9  9  Texas  26,957  -----1  3  253  126   Mountain  23,197  ------1  157  126  Arizona  6,731  ------1  80  27  Colorado  5,356  -------46  72  Idaho  1,634  -------6  13  Montana  1,024  -------2  3  Nevada  2,839  -------3  -New Mexico  2,086  -------19  5  Utah  2,943  -------1  1  Wyoming  584  --------5   Pacific  51,992  -------575  247  Alaska  737  ---------California  38,803  -------561  240  Hawaii  1,420  --------1  Oregon  3,970  -------7  1  Washington  7,062  -------7  5 Territories American Samoa 55 --1  -1  336  --Connecticut  -N  ---188  --Maine  -----44  --Massachusetts  --1  -1  ---New Hampshire  --N  N  N  23  --Rhode Island  ----- The age-adjusted death rates for Parkinson disease increased for males from 8.8 per 100,000 population in 2000 to 11.0 in 2013 and for females from 3.9 in 2000 to 4.8 in 2013. From 2000 to 2013, the rates increased for black and white males and black and white females. Throughout the period, the rate for males was higher than the rate for females and the rates for whites were higher than those for blacks. Deaths per 100,000 pop. 
